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Summary.-A radioimmunoassay (RIA) for cytosine arabinoside (AraC) has been
developed using antiserum raised in a sheep to an AraC monophosphate-ovalbumin
conjugate. The antibody shows only 0.008% cross-reactivity with uracil arabinoside
(AraU) and low (0 023%) cross-reactivity with other commonly co-administered
drugs such as cytotoxic and antibacterial agents, and also a number of naturally
occurring nucleosides and nucleotides. It does however cross-react by 125% with
AraC monophosphate and by 109% with AraC triphosphate. As little as 1 ng/ml of
AraC can be detected in plasma, serum, urine and cerebrospinal fluid (CSF) with no
need for prior extraction. This RIA has been used to follow the disappearance of
AraC from the plasma of patients receiving the drug.
CYTOSINE ARABINOSIDE (AraC) has been
used successfully in the treatment of
lymphoma and acute myelogenous leu-
kaemia. The drug is converted rapidly in
the blood, either being deaminated to
form inactive uracil arabinoside, or phos-
phorylated by kinases to the active tri-
phosphate form. The pharmacokinetics of
AraC have been demonstrated in several
studies (Ho & Frei, 1971; Wan et al., 1974;
Dedrick et al., 1972). The major cytotoxic
effect of AraC triphosphate has been
shown to be its competition with deoxy-
cytidine triphosphate for DNA polymerase
(Furth & Cohen, 1968). Resistance to
AraC has frequently been demonstrated,
and several possible causes have been
shown to exist. A larger than normal pool
size of deoxycytidine nucleotides has been
reported in resistant cells (Momparler et
al., 1968; Tattersall et al., 1974). A reduced
affinity of DNA polymerase for AraCTP
has been shown (Bach, 1969) and reduced
deoxycytidine kinase levels and increased
cytidine deaminase levels have been
demonstrated (Chu & Fischer, 1965;
Meyers etal., 1973; Steuart & Burke, 1971).
The routine monitoring of circulating
AraC during an infusion of the drug or
after i.v. bolus injection would seem to be
of value in assessing whether therapeutic
levels have been reached and whether,
after repeated administration, the same
dose/blood level is maintained or there is
increased deamination.
Such routine monitoring has not been
possible withprevious methodsformeasur-
ing AraC. These methods have been micro-
biological (Hanka, 1971), enzymatic(Mom-
parler et al., 1972), paper or thin-layer
chromatography followed by the counting
of radiolabelled products or UV absorb-
ance (Ho & Frei, 1971; Dedrick et al.,
1]972; Notari, 1967) and high-performance
liquid chromatography (Kreis et al., 1977).
Gas-liquidchromatographyand mass spec-
troscopy have also been used (Boutagy &
Harvey, 1978). Immunoassay is probably
the best method for routine monitoring
for cytotoxic drug levels (Teale et al., 1977;
Aherne et al., 1977).
In this paper, the development and
application of an RIA for AraC is de-
scribed which is more sensitive than pre-
vious methods for assay of AraC, and is
quick to perform.RADIOIMMUNOASSAY FOR CYTOSINE ARABINOSIDE
MATERIALS AND METHODS
Chemicals.-AraC was kindly supplied by
Upjohn Ltd. AraU was a gift of Dr A. Harris
of Oxford. AraCMP, AraCTP, cytidine, 2-
deoxycytidine, D-arabinose and other nucleo-
sides and nucleotides were purchased from
Sigma Chemicals Ltd, as was Norit A
charcoal and ethyl (dimethyl amino propyl)-
y-carbodiimide (EDC). The deaminase in-
hibitor THU was bought from Calbiochem.
5-[3H] cytosine /3-D-arabinoside (TRK 348,
15 Ci/mmol) was obtained from the Radio-
chemical Centre, Amersham. Dextran T-70
was bought from Pharmacia Ltd, and other
reagents were obtained from BDH Chemicals
Ltd, May and Baker Ltd and Packard.
Plasma samples were obtained from patients
who were attending the Nuffield Department
ofClinicalMedicine atthe Radcliffe Infirmary,
Oxford. They had no previous chemotherapy
and the only cytotoxic agent they were
receiving was Ara C. Blood was taken into
tubes containing THU.
Production of immunogen.-The conjugate
used for immunization was an AraC mono-
phosphate-ovalbumin preparation, made ac-
cording to the method of Halloran & Parker
(1966). Ovalbumin (113 mg, 2-5 ,umol), Ara-
CMP (20 mg, 61-9 ,mol) and EDC (136 mg,
2X5 ,umol) were dissolved in 2 ml of 0-05M
phosphate buffer, pH 7 5, and mixed for 18 h
in the dark. The conjugate was then dialysed
against 3 x 11 changes of distilled water. The
amount of AraCMP conjugated to ovalbumin
was calculated from absorbance measure-
ments at 260 nm and was found to be 8 mol
AraCMP per mol ovalbumin. The conjugate
was stored as a liquid at 4°C at a concentra-
tion of5 mg/ml.
Immunization.-Two half-lop rabbits were
immunized with 5 mg and 2 with 2 mg
conjugate in 0 5 ml sterile water emulsified
with 1 ml Marcol 52 adjuvant (Robinson et
al., 1975) containing 3 mg BCG. They were
injected i.m. and s.c. into 4 sites on the back
legs and shoulders. They were given boosters
of 1-0-5-0 mg conjugate at intervals of 1-10
months, and bled from the marginal ear vein
8 days after each boost and at roughly
monthly intervals between boosts. Three
sheep were immunized with 5 mg conjugate
in 1 ml sterile water, emulsified with 2 ml
Marcol 52 adjuvant containing 3 mg BCG.
They were injected i.m. in multiple sites in the
legs and back. They were given boosters of
2-5 mg of the conjugate at two 3 monthly
intervals and bled from the jugular vein
8 days after each injection. The blood was
allowed to clot, the serumseparatedandstored
at 4°C with 0.1% sodium azide.
Radioimmunoassay.-The buffer diluent
used throughout the assay was 0-05M phos-
phate buffer, pH 7 4, containing 0-6 g%
(w/v) NaCl and 0-1 g% (w/v) gelatin. The
protocol used is shown in Table I. Oxford®
pipettes and the Compupet ® (Warner Diag-
nostics Ltd) were used for all dilutions and
additions. A freeze-dried standard was used,
a concentrated stock solution being suitably
diluted and aliquots prepared for freeze-
drying. After reconstitution, the standard
was further diluted to give standard curve
points, each point being set up in duplicate.
Samples, stored at -18°C, were assayed at
3-4 dilutions, each dilution set up in dupli-
cate. Antiserum was kept at 4°C, the amount
to be used for standard curves being estab-
lished by antiserum dilution curves as that
dilution which bound 40% ofthe added label.
[3H] AraC (15 Ci/mmol) was stored as con-
centrated stock solutions in 3% ethanol:
water at -10°C and diluted in buffer fresh
for use in each assay, so that 041 pmol (24.3
pg) AraC was added to each assay tube.
Dextran-coated charcoal (DCC) was pre-
pared as follows: 25 g/l Norit A charcoal and
2-5 g/l Dextran T-70 were stirred overnight
in the cold in 0-05M phosphate buffer, pH 7-4.
The mixture was then centrifuged and the
supernatant decanted off to remove the fines.
The coated charcoal was resuspended in the
same volume of buffer which was originally
used, and stored at 4°C until required.
To set up the assay, the reagents were
added in the order indicated in Table I to
LP3 plastic tubes (Luckham Ltd), and the
contents mixed and left at room temperature
for 50 min. The tubes were then placed in an
ice-filled trayfor 10 min.DCCwasresuspended
over a magnetic stirrer, and added rapidly to
the tubes during stirring. The assay tubes
were mixed again and replaced in ice for 15
min, when they were centrifuged at 4°C for
10 min. 500,il aliquots of supernatant were
taken for liquid-scintillation counting in an
L.K.B. Ultrobeta or a Packard (2425)
counter. The scintillant used was 2 parts of
sulphur-free toluene to 1 part of Metapol
detergent (Durham Chemicals Distributors
Ltd) containing 0.53% w/v PPO and 0.01%
w/v POPOP. Counts were found to be stable
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TABLE I.-Procedurefor RIA of AraC
Zero tube
or Standard
Total Non-specific Maximum antiserum or
counts binding binding dilution sample
Reagent tube tube tube curve tube
Diluent buffer 600 500 100 400 300
Standard or sample - - 100
Antiserum - 400 100 100
[3H] Ara C (0-1 pmol) 100 100 100 100 100
Incubate 50 min at room temp. followed by 10 min at 4°C.
DCC (2.5%) - 100 100 100 100
Leave for 15 min in ice, centrifuge and count 500 ju supernatant.
over a period of 10 h after which a decline
occurred, due, it is thought, to self-absorption
by the clumping of precipitating material.
RESULTS
Antiserum production
The immunogen stimulated the produc-
tion ofantibody in 3/7 animalsimmunized.
One rabbit and one sheep produced anti-
body in too low a titre for practical use,
but the third animal, a sheep (G/S/747),
after its third immunization produced
antibody which could be used in an assay
ataninitialdilutionof1/80. Thenonspecific
binding (NSB) of G/S/747 serum before
immunization was less than 5% of total
counts added, the same as for the buffer
diluent used in the assay.
Radioimmunoassay
A typical displacement curve is shown
in Fig. 1. The results are expressed as a
percentage of [3H] AraC bound in the
zero tube. The avidity of the antiserum
for AraC as determined by a Scatchard
plot of the curve shown was 1-68 x 109 1/
mol.
The sensitivity of the assay as deter-
mined bythe method ofAlbano and Ekins
(1970) was 309 pg/ml. The addition of
normal human plasma or serum to the
displacement curve caused a reduction in
sensitivity and when 50 ,ul, the maximum
amount ofplasma or serum added per tube
for unknowns, was added to the displace-
ment curve, the sensitivity was 990 pg/ml.
Thus when plasma or serum samples with
low AraC levels (10 ng/ml or less) were
assayed, necessitating the addition of 10
to 50 ul of undiluted sample to the assay
tubes, a displacement curve with 50 ,u of
normal human serum added to each tube,
was set up. Normal serum was added to
each unknown tube to make a total of
50 ,ul per tube, and the "serum curve" was
used for calculation of results. Addition of
less than 10 jzd of serum did not affect the
displacement curve, so serum samples in
which 10 ,ul or less ofthe sample was added
per tube, were calculated off a curve with
no added serum.
The addition of 10 pl and 50 ul ofpooled
normal human urine to the NSB tubes
showed a great increase in label bound-
up to 25%-but provided the appropriate
NSB was set up andusedin the calculation
of standard curves and unknowns, good
recoveries were obtained from urine when
even a low level of AraC was present,
and there was no reduction in sensitivity
ofthe assay.
CSF was obtained as a pool from acute
lymphocytic leukaemia (ALL) patients
who had not received AraC, and made no
alteration in NSB or sensitivity of the
displacement curvewhenaddedinamounts
up to 50 pl. Recovery of AraC added to
serum, urine and CSF was complete over
a 100-fold range without prior extraction,
as shown in Table II.
Incubation time of the assay is given in
Table I as 50 min+ 10 min in ice, but
identical results were obtained when this
was reduced to 10 min at room temp+10
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between 10 and 20 mininice, a slow reduc-
tion in binding occurring after 20 min.
Normal human serum containing known
amounts ofAraC was stored at 4°C and at
-18°C in tubes without the addition of
THU, the deaminase inhibitor. The lOOng/
ml samples stored at -18'C gave only a
54% recovery, and the 500ng/ml sample
gave a 59-4% recovery, after 2 months.
Even lower recoveries were obtained from
tubes stored at 4°C. Serum containing
THU gave 100% recoveries when re-
frozen and re-assayed after being stored
for a further 2-3 months. The variation
of 5 separate standard curves set up
within a single assayrun is shown in Table
III. Inter-assay variation over 5 standard
curves carried out on consecutive days is
shown for comparison. Cross-reactivity
ofthe G/S/747 III B antiserum used in the
assay was assessed with a wide range of
compounds, including related nucleosides
and nucleotides, and drugs which might
be co-administered to the patient, such
as other cytotoxic drugs, antibiotics,
tranquillizers, analgesics, and THU, which
is added to each blood sample to prevent
deamination. Cross-reactivity is expressed
as a percentage of that amount of AraC
required to cause the same inhibition of
binding. In Table IV the cross-reactants
tested are listed, with their % cross-
reactivity at 50% inhibition of binding.
5 10 15 20
Ara C ng/mI
FIG. l.-Inhibition ofbinding of[3H]AraC by
addition of increasing amounts of AraC.
Final dilution of antiserum G/S/747 IIIB
was 1: 360. 01 pmol [3H]AraC was added
to each tube. No plasma/serum present,
* *; 50 ,ul pooled normal human
serum added, O; 25 ,ul pooled normal
human serum added, A.
min in ice, even in the presence of human
serum. Longer periods, including an over-
night stay in a 4°C cold room, could also
be used with no alteration of binding, if
this proved more convenient. Length of
time over DCC was found to be optimum
The measurement of AraC in clinical
samples
Plasma from 20 AML patients who had
received AraC by i.v. bolus and by i.v.
infusion has been assayed by the RIA.
The plasma disappearance of AraC after
a single i.v. bolus injection of 2-0 mg/kg
has been measured in 16 patients. Dis-
appearances in 2 patients are shown in
Fig. 2. Further results will be published at
a later date.
DISCUSSION
The AraCMP-ovalbumin conjugate has
shown variable immunogenicity in the 7
animals used for immunization. The anti-
0
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TABLE II.-Recovery of AraC. Percentage recovered + CV (n)
AraC added
(ng/ml) Serum
10 85-0+ 21-4 (3)
100 100-0+ 6-2 (3)
500 94-7+10-8 (6)
1000 83-1+10-6 (6)
Urine
93-3+22-7 (3)
97-3+6-8 (3)
90-8+ 2-1 (3)
97-2+ 12-1 (3)
CSF
107-2 (2) 109-8, 104-6
97-2+4-1 (5)
103-4+ 17-2 (5)
102-2+12-7(6)
TABLE III.-Intra- and inter-assay variation of AraC standard curves (n= 5)
ng added
0 0-05
Intra-assay variation
S.d. 1-37 2-16
CV% 2-8 2-4
Inter-assay variation
S.d. 5.3 7 1
CV% 11-8 83
0-1 0-2 0-3 0-4 0-5 0-7 1-0 1-5 2-0
3-6 54 3-8 3-0 21 1.1 0-85 1-4 0-96
47 95 8-7 8-8 73 5-0 49 10-8 10-4
5.4 3-2 26 1.1 16 0-99 081 1-2
75 59 6-2 3-3 6-0 4-5 4-9 100
0 4
4.5
TABLE IV.-Inhibition of antiserum bind- high, enabling a sensitive assay of relia-
ing of [3H]AraC by AraC and other bility and good reproducibility to be
compounds developed. The antibody appears to recog-
% cross- nize the whole of the hapten used in
reactivity conjugation, as it cross-reacts by 125%
inthibiton with AraCMP, and 109% with AraCTP,
Cytosine arabinoside 100 while not recognizing AraU, which differs
Cytosine arabinoside monophosphate 125 from AraC by only deamination at the 4
Cytosine arabinoside triphosphate 109 position (Fig. 3). Its recognition ofcytidine Uracil arabinoside < 0-008
Cytosine <0-02 and deoxycytidine, which closely resemble
D-arabinose <0-19 AraC, is very limited, cross-reactivity
Cytidine; cytidine 5'-monophosphoric being less than 0.19%. The cross-reaction
acid; 2-deoxycytidine; 2- deoxy-
cytidine monophosphoric acid < 0-19 with the active metabolites of AraC
Thymine; adenosine diphosphate; (AraCMP and AraCTP) does not interfere
adenosine triphosphate; with following AraC levels in plasma or guanosine-3',5'-cyclic
monophosphate <0-002 serum, as these nucleotide derivatives are
Adenosine 3',5'-cyclic monophosphate <0-0044 found only in cells, being unable to cross
Tetrahydrouridine < 0-03 cell membranes (Bender et al., 1978) and, 6-Mercaptopurine, methotrexate,
5-fluorouracil, adriamycin, bleomycin, unless lysis has occurred, should not be
vincristine, vinblastine < 0-02 present in the sample for assay. Use
Prednisolone < 0-02
Morphine, codeine <0-02 of the cross-reaction will be made, how-
Diazepam,nitrazepam <0-02 ever, as it is intended (by using HPLC)
Tetracycline <0-02 to separate AraC from its active metabo-
Ampicillin <0-012 lites in cells and measure their levels by
Benzylpenicillin; gentamicin; RIA. This will prove of interest in follow-
sulphate <n0-002 ing individual patients' rates of conversion
ofAraC to the nucleotides and may or may
serum obtained from sheep G/S/747 has not support the theory of prediction of
not yet shown a high titre. After a priming resistance by measurement of rates of
dose and 3 boosters, it has reached a titre conversion of the drug to its active forms.
of 1-780 final dilution, and it is hoped that Plasma half-lives for AraC after i.v. bolus
this will increase with further boosters. injection of the drug have been reported
However, the avidity of the antiserum is by various groups. Plasma disappearance
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PATIENT C
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0 20 40 60 80 100 120 180 240 0 20 40 60 80 100120 180 240
Time (min) Time (min)
FIG. 2.-Disappearance of AraC from the plasma of 2 AML patients after single i.v. bolus injection
at Time 0. Both patients received 2 mg/kg of AraC.
has generally been accepted as following
first-order kinetics, a biphasic curve occur-
ring. Ho & Frei (1971) report an initial ti
of 12 min, followed by a second phase with
a ti of 111 min. Wan et al. (1974) also
report a biphasic disappearance, with
one ti of 7 min and a second ti of 157 min.
Plasma disappearances obtained by this
RIA for 16 patients show triphasic or
multiexponential curves over the time
studied. All concentrations below 10 tg/l
were excluded from the evaluation of the
curves, as it was felt that these low values
could be criticized because of the low and
variable recovery obtained at this level
(85.0% with a coefficient of variation of
21.4%). The curves were analysed by the
slope of the line of best fit between points
using a specific programme on a Wang
2200 computer. It seems probable that
previous methods of measuring AraC
were insufficiently sensitive to detect
small changes in AraC level during its dis-
appearance, and thus the smooth biphasic
curves were obtained.
Positive AraC levels (2-7-5-1 ng/ml)
were measured by RIA at time zero in the
plasma of some AML patients who had
not previously received the drug. These
positive-zero plasmas all gave NSB values
of 6% or less, so the binding displayed
must have been of a specific nature. Forty
serum and plasma samples from normal
subjects and from ALL patients who had
not received AraC were assayed and none
displayed any binding. The cause of these
apparently false positive AraC values is
not yet known, as the antibody shows such
a high degree of specificity for AraC. It is
possible that the zero levels should be
subtracted from all levels of AraC in the
following disappearance curve. The pres-
ence ofAraC would still be detectable after
4 h in the plasma of most patients studied.
Further investigation into what causes the
positive levels at time zero is continuing.
10,000
pg/1
1,000
100
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FiG. 3. Structures of cytosine arabinoside, 2 of its metabolites (AraU and AraC monophosphate)
and 2 naturally occurring nucleosides-cytidine and deoxycytidine.
The reduction in recovery from serum
containing AraC but no THU, even when
stored at - 18°C, demonstrates the neces-
sity for the addition of the inhibitor to
blood samples, preferably by adding THU
to sampling tubes to achieve a final con-
centration of 1 mm (0-25 mg/ml blood).
The amount of AraC bound to plasma
proteins has been found to be only 13%
regardless of drug concentration (van
Prooijen et al., 1977). Experiments to con-
firm whether the RIA measures the bound
as well as free drug have not yet been
made. Because of the high avidity of the
antiserum, it is almost certain that bound
drug is measured.
The advantages of RIA over other
available methods for measuring AraC
are considerable. Other methods have all
suffered from a lack of the sensitivity
required to follow AraC levels for more
than about 4 h, or have been too time-
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consuming forroutine use. The administra-
tion of radiolabelled AraC to patients has
been necessary for some of the chromato-
graphic methods, a procedure which is not
always acceptable. Some methods have
suffered from interference by co-adminis-
tered drugs, such as the interference by
antibacterial agents in the microbiological
methods. Gas-liquid chromatography and
mass spectroscopy are of limited applica-
tion as they require expensive equipment
only available in a few centres and highly
trained technical staff. RIA, besides
having a great advantage over all the
above-mentioned methods by virtue of
its sensitivity and lack of interference by
co-administered drugs, is ideally suited
for routine monitoring purposes, as it is
easy to deal quickly with large numbers of
samples, and the only special equipment
required is a liquid scintillation counter,
which is available in most hospital
laboratories. An RIA for AraC has already
been reported (Okabayashi et al., 1977) in
which it was necessary to extract AraC
from serum into ethanol, and in which the
separation of free and antibody-bound
AraC was performed by Millipore filters.
No extraction is required for the RIA
described in this paper, and the use of
DCC for the separation of free and bound
AraC is extremely rapid. These two factors
make this RIA highly suitable for routine
monitoring, especially where results are
required quickly, e.g. within 3 h of
sampling.
The authors hope that clinical use will
be made of this method to follow plasma
levels of AraC, CSF levels of the drug in
acute leukaemia patients with CNS in-
volvement, and also possibly in detecting
increasing deaminase levels in resistant
patients.
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